



DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICALS & SOLVENTS

GST No.: 27AAACA5253A1Z9

CIN No.: L99999MH1990PLC056538

HEAD OFFICE.: 1227, HUBTOWN SOLARIS, N. S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA. ☎ : (022) 62872900/2999 E-mail : info@aaeydrugs.com
REGD. OFFICE & FACTORY: E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR- 401 506. ☎ : (02525) 652165 E-mail : works@aaeydrugs.com Web : www.aaeydrugs.com

Date: 13/02/2021

To,
The Manager,
Corporate Service Department
BSE Limited
P.J. Towers, Dalal Street,
Mumbai- 400 001

Scrip Code: 524412

Sub: Unaudited Financial Results for the Quarter ended 31st December, 2020.

Dear Sir/Madam,


Pursuant to the Regulation we are enclosing herewith the Unaudited financial results for the quarter ended 31st December, 2020 with Limited Review Report.

Please take on record of the same and oblige.

Thanking you,

Yours Faithfully,

For Aarey Drugs & Pharmaceuticals Ltd


Mihir Ghatalia
Managing Director
DIN: 00581005



Encl.: a/a

HEAD OFFICE.: 1227, HUBTOWN SOLARIS, N. S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA. ☎ : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY: E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR- 401 506. ☎ : (02525) 652165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2020 (Rs. In Lakhs except EPS)						
Particulars	3 months ended on 31.12.2020	3 months ended on 30.09.2020	3 months ended on 31.12.2019	9 months ended on 31.12.2020	9 months ended on 31.12.2019	Previous year ended on 31.03.2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Revenue from Operations	9,512.30	4,982.40	5,964.82	17,016.47	18,940.77	30,008.88
Other Income	208.96	254.96	84.57	537.66	327.20	668.92
TOTAL INCOME	9,721.26	5,237.35	6,049.39	17,554.13	19,267.97	30,677.80
EXPENSES						
Cost of Materials Consumed	10,050.11	5,367.55	5,582.25	17,576.46	18,040.72	29,018.16
Changes in Inventories	-873.06	-527.33	-	-1,299.29	-	-
General Administrative Expense	23.90	11.63	124.71	59.88	293.20	472.04
Selling and Distribution Exp	209.55	66.95	37.76	297.71	115.18	198.30
Finance Cost	60.88	80.07	50.49	187.59	138.75	175.72
Depreciation and Amortization Expense	22.35	22.35	25.43	67.05	78.15	89.39
Other Expenses	57.19	31.56	88.54	153.96	122.17	-
TOTAL EXPENSES	9,550.93	5,052.78	5,909.18	17,043.37	18,788.17	29,953.61
Profit Before Exceptional Items and Tax	170.33	184.57	140.21	510.76	479.80	724.19
Exceptional Items	-	-	-	-	-	-
Profit / (Loss) Before Tax	170.33	184.57	140.21	510.76	479.80	724.19
Tax Expenses						
a) Current Tax	-	-	-	-	-	-150.00
b) Deferred Tax	-	-	-	-	-	5.16
Profit / (Loss) for the period from continuing operations	170.33	184.57	140.21	510.76	479.80	579.35
Profit/(loss) from discontinued operation	-	-	-	-	-	-
Tax expense of discontinued operation	-	-	-	-	-	-
Profit/(loss) from Discontinued operations (after tax)	-	-	-	-	-	-
Profit/(loss) for the period	170.33	184.57	140.21	510.76	479.80	579.35
Other Comprehensive Income						
A. a) Items that will not be classified to profit and loss	-	-	-	-	-	-
b) Income tax relating to Items that will not be reclassified to Profit or loss	-	-	-	-	-	-
B. a) Items that will be classified to profit and loss	-	-	-	-	-	-
b) Income tax relating to Items that will be reclassified to Profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the year	170.33	184.57	140.21	510.76	479.80	579.35
Earnings per equity share (for continuing operation): (of Rs. 10/- each) (for the period/year): *						
a) Basic EPS (Rs.)	0.73	0.79	0.60	2.18	2.05	2.48
b) Diluted EPS (Rs.)	0.73	0.79	0.60	2.18	2.05	2.48
Earnings per equity share (for discontinued operation): (of Rs. 10/- each) (for the period/year): *						
a) Basic EPS (Rs.)	-	-	-	-	-	-
b) Diluted EPS (Rs.)	-	-	-	-	-	-
Earnings per equity share (for discontinued & Continuing operation): (of Rs. 10/- each) (for the period/year): *						
a) Basic EPS (Rs.)	0.73	0.79	0.60	2.18	2.05	2.48
b) Diluted EPS (Rs.)	0.73	0.79	0.60	2.18	2.05	2.48
Number of Shares	23,384,684	23,384,684	23,384,684	23,384,684	23,384,684	23,384,684
Percentage of Shareholding	100%	100%	100%	100%	100%	100%
Paid-up Equity Share Capital (FV of Rs. 10/- each)	233,846,840	233,846,840	233,846,840	233,846,840	233,846,840	233,846,840



***Not Annualised**

Notes :

1. The above Unaudited Financial results of the Company for the quarter and nine months ended 31 December, 2020 have been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on 13th February, 2021.
2. The aforesaid unaudited financial results for the quarter ended and nine months ended 31 December, 2020 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of SEBI (Listing Obligation and disclosure Requirements) Regulations, 2015.
3. The unaudited results for the quarter ended 31 December, 2020 have been subjected to limited review by the Statutory Auditors of the Company.
4. The Company operates only in one segment, i.e. Manufacturing and Trading of Drugs & Pharmaceutical and all other allied activities revolving around the same. As such there is no other separate reportable segment as defined by IND AS 108- "Operating Segments."
5. Expenses in relation to Employee Benefit are categorized under General & Admin Expenses as per the judgement of the Management of the Company.
6. Income Tax and Deferred Tax, if any, will be provided at the end of the year.
7. Status of Investor Complaints (Nos): Opening Balance as on 01.10.2020 - Nil ; Received During the Quarter - Nil ; Disposed Off During the Quarter - Nil ; Closing Balance as on 31.12.2020 - Nil.
8. The Figures of the previous year and/or period(s) have been regrouped wherever necessary.

Place: Tarapur

Date: 13th February 2021



By order of the Board of Directors

Mihir R Ghatalla
Managing Director
DIN: 00581005



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
FINANCIAL RESULTS**

To

The Board of Directors,
Aarey Drugs and Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Aarey Drugs and Pharmaceuticals Limited** ("the Company") for the quarter and nine month ended December 31, 2020 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended, read with Circular No.CIR/CFD/CMD1/44/2019 dated 29th March 2019 ("the 'Circular'").
2. This Statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind-AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Other Matters

The Review Report for the quarter ended 31st December, 2020 is our first Report for the Company. Financial Results for the quarter ended 30th September, 2020 and prior periods were reviewed / audited by the previous Statutory Auditor. We have relied upon Limited Review Reports / Audit Reports of the preceding Auditor for all such previous periods.

Our Conclusion is not modified with respect to this matter.

For Motilal & Associates
Chartered Accountants
Firm Registration No. 106584W



Motilal Jain
Partner
Membership No.036811



Place : Mumbai
Date :13thFebruary, 2021

UDIN : 21036811AAAAEA7123

**Aarey****DRUGS & PHARMACEUTICALS LTD.**MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICALS & SOLVENTS

GST No.: 27AAACA5253A1Z9

CIN No.: L99999MH1990PLC056538

HEAD OFFICE.: 1227, HUBTOWN SOLARIS, N. S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA. ☎ : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY: E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR- 401 506. ☎ : (02525) 652165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com**Reconciliation of Net Profit as per IND AS and IGAAP****(Rs. in Lakhs)**

S.No.	Particulars	Quarter Ended		Year Ended
		31-Dec-2020	30-Sept -2020	31-Mar-2020
1	Net Profit/(loss) after tax for the period as per IGAAP	170.33	184.57	579.35
2	Impact of IND AS on comprehensive Income	-	-	-
3	Impact of IND AS on other comprehensive Income	-	-	-
4	Total comprehensive income for the period as per IND AS	170.33	184.57	579.35

Place: Mumbai

Date: 13th February 2021

Certificate of Managing Director (MD)

I, Mihir R. Ghatalia, Managing Director (MD) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 31st December, 2020 and to the best of my knowledge and belief:
 - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
 - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.




Mihir R. Ghatalia
Managing Director
Date: 13/02/2021
Place: Mumbai

Certificate of Chief Financial Officer (CFO)

I, Mira M Ghatalia, Chief Financial Officer (CFO) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 31st December, 2020 and to the best of my knowledge and belief:
 - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
 - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



Mira M. Ghatalia

CFO

Date: 13/02/2021

Place: Mumbai